Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients

Oncology Reports

Volumn 31, Issue 3, 2014, Pages 1263-1270

  Song, Q I Chun ^a   Shi, Zhi Bin ^a   Zhang, Yong Tao ^a   Ji, L E ^a   Wang, Kun Zheng ^a   Duan, D A Peng ^b   Dang, Xiao Qian ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

Author keywords

EZH2; Metastasis; miR 26a; Osteosarcoma; Prognosis

Indexed keywords

MICRORNA 26A; TRANSCRIPTION FACTOR EZH2;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE MARKER; DISTANT METASTASIS; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SURVIVAL RATE; TUMOR INVASION; UPREGULATION;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; BINDING SITES; BONE NEOPLASMS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OSTEOSARCOMA; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; RNA INTERFERENCE;

EID: 84896696822     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.2989     Document Type: Article

References (36)

1. Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543, 2009.
2. Teicher BA: Searching for molecular targets in sarcoma. Biochem Pharmacol 84: 1-10, 2012.
3. Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9: 422-441, 2004. (Pubitemid 39014554)
4. Gorlick R: Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res 152: 467-478, 2009.
5. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006. (Pubitemid 44629897)
6. Kumar MS, Lu J, Mercer KL, Golub TR and Jacks T: Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39: 673-677, 2007. (Pubitemid 46676103)
7. Tang M, Lin L, Cai H, Tang J and Zhou Z: MicroRNA-145 downregulation associates with advanced tumor progression and poor prognosis in patients suffering osteosarcoma. Onco Targets Ther 6: 833-838, 2013.
8. Shen L, Chen XD and Zhang YH: MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN. Tumour Biol: Oct 15, 2013 (Epub ahead of print).
9. Wang Y, Zhao W and Fu Q: miR-335 suppresses migration and invasion by targeting ROCK1 in osteosarcoma cells. Mol Cell Biochem 384: 105-111, 2013.
10. Kota J, Chivukula RR, O'Donnell KA, et al: Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017, 2009.
11. Ji J, Shi J, Budhu A, et al: MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361: 1437-1447, 2009.
12. Ciarapica R, Russo G, Verginelli F, et al: Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle 8: 172-175, 2009.
13. Zhang B, Liu XX, He JR, et al: Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 32: 2-9, 2011.
14. + T cell ready to battle hepatocellular carcinoma. Hepatology 58: 1-3, 2013.
15. Liu B, Wu X, Liu B, et al: MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim Biophys Acta 1822: 1692-1704, 2012.
16. Huse JT, Brennan C, Hambardzumyan D, et al: The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 23: 1327-1337, 2009.
17. Zhang J, Han C and Wu T: MicroRNA-26a promotes cholangiocarcinoma growth by activating β-catenin. Gastroenterology 143: 246-256, 2012.
18. Lu J, He ML, Wang L, et al: MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 71: 225-233, 2011.
19. Sander S, Bullinger L, Klapproth K, et al: MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112: 4202-4212, 2008.
20. Luzi E, Marini F, Sala SC, Tognarini I, Galli G and Brandi ML: Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor. J Bone Miner Res 23: 287-295, 2008. (Pubitemid 351160043)
21. Gorlick R, Anderson P, Andrulis I, et al: Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 9: 5442-5453, 2003. (Pubitemid 37499462)
22. Wittig JC, Bickels J, Priebat D, et al: Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician 65: 1123-1132, 2002.
23. Sreekumar R, Sayan BS, Mirnezami AH and Sayan AE: MicroRNA control of invasion and metastasis pathways. Front Genet 2: 58, 2011.
24. Chang TC, Yu D, Lee YS, et al: Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43-50, 2008.
25. Dews M, Homayouni A, Yu D, et al: Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38: 1060-1065, 2006. (Pubitemid 44325933)
26. Xu H, Yao Y, Smith LP and Nair V: MicroRNA-26a-mediated regulation of interleukin-2 expression in transformed avian lymphocyte lines. Cancer Cell Int 10: 15, 2010.
27. Dang X, Ma A, Yang L, et al: MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet 205: 113-123, 2012.
28. Sparmann A and van Lohuizen M: Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6: 846-856, 2006. (Pubitemid 44629896)
29. Kleer CG, Cao Q, Varambally S, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11611, 2003. (Pubitemid 37205983)
30. Raaphorst FM, Meijer CJ, Fieret E, et al: Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 5: 481-488, 2003. (Pubitemid 38045085)
31. Xu C, Hou Z, Zhan P, et al: EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer. Med Oncol 30: 713, 2013.
32. Wagener N, Macher-Goeppinger S, Pritsch M, et al: Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10: 524, 2010.
33. Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
34. Richter GH, Plehm S, Fasan A, et al: EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA 106: 5324-5329, 2009.
35. Croonquist PA and Van Ness B: The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24: 6269-6280, 2005. (Pubitemid 43080050)
36. Sasaki H, Setoguchi T, Matsunoshita Y, Gao H, Hirotsu M and Komiya S: The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth. Oncol Rep 23: 677-684, 2010.